Back to Search
Start Over
Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature
- Source :
- Lupus. 29(6)
- Publication Year :
- 2020
-
Abstract
- Objective The purpose of this study was to characterize the role of eculizumab, a monoclonal antibody against the terminal complement component C5, in patients with catastrophic antiphospholipid syndrome (CAPS). Methods We present a case report of a patient with systemic lupus erythematosus (SLE) and CAPS treated with eculizumab, as well as results of a systematic review of the literature. Results Including our patient, we identified 11 case reports of patients with CAPS treated with eculizumab. All of them had partial or total remission of symptoms. Conclusion Data on eculizumab efficacy in CAPS are promising but are limited to single case reports. More studies are needed to develop evidence-based recommendations for eculizumab use in CAPS.
- Subjects :
- Adult
Male
medicine.medical_specialty
Thrombotic microangiopathy
medicine.drug_class
030204 cardiovascular system & hematology
Catastrophic antiphospholipid syndrome
Monoclonal antibody
Antibodies, Monoclonal, Humanized
Gastroenterology
Severity of Illness Index
03 medical and health sciences
0302 clinical medicine
Rheumatology
Internal medicine
medicine
Humans
Lupus Erythematosus, Systemic
In patient
Aged
030203 arthritis & rheumatology
business.industry
Thrombotic Microangiopathies
Remission Induction
Complement C5
Eculizumab
Middle Aged
medicine.disease
Antiphospholipid Syndrome
Treatment Outcome
Complement component C5
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 14770962
- Volume :
- 29
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Lupus
- Accession number :
- edsair.doi.dedup.....e14597bd323baa5841bd7c2bd7c5e66d